Menopause before the age of 45 years is considered to be "early menopause" and when ovarian failure/surgical removal of the ovaries occurs before the age of 40 years this is termed "premature ovarian insufficiency".In addition symptoms (hot flushes/flashes, night sweats, mood changes, arthralgia and vaginal dryness) the physical consequences of menopause include bone loss, increased central abdominal fat, and adverse changes in a womans cholesterol profile and vascular function. These changes predispose postmenopausal women to increased risks of osteoporosis and fracture and cardio-metabolic disease (diabetes and cardiovascular disease).Menopause is usually a natural change. It can occur earlier in those who smoke tobacco. Other causes include surgery that removes both ovaries or some types of chemotherapy. At the physiological level, menopause happens because of a decrease in the ovaries production of the hormones estrogen and progesterone. While typically not needed, a diagnosis of menopause can be confirmed by measuring hormone levels in the blood or urine. Menopause is the opposite of menarche, the time when a girls periods start.The primary indications for treatment of menopause are symptoms and prevention of bone loss. Mild symptoms, however, may be improved with treatment. With respect to hot flashes, avoiding smoking, caffeine, and alcohol is often recommended. Sleeping in a cool room and using a fan may help. The most effective treatment for menopausal symptoms is menopausal hormone therapy (MHT). Non hormonal therapies for hot flushes/flashes include clonidine, gabapentin, or selective serotonin reuptake inhibitors.
Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand name Yasmin among others, is a combination of ethinylestradiol (EE), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used as a birth control pill to prevent pregnancy in women. It is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation) in women. The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others). A formulation with levomefolic acid (vitamin B9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications. EE/DRSP is marketed widely throughout the world.In 2019, it was the 148th most commonly prescribed medication in the United States, with more than 4 million prescriptions. See also
Ethinylestradiol/drospirenone/levomefolic acid
Ethinylestradiol/drospirenone/prasterone
Estradiol/drospirenone
List of combined sex-hormonal preparations § Estrogens and progestogens

References
External links
"Drospirenone mixture with estradiol". Drug Information Portal. U.S. National Library of Medicine.